List of Excipients in Branded Drug ISOPTO CARPINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	ISOPTO CARPINE	pilocarpine hydrochloride	0998-0203	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	ISOPTO CARPINE	pilocarpine hydrochloride	0998-0203	BORIC ACID
Alcon Laboratories Inc	ISOPTO CARPINE	pilocarpine hydrochloride	0998-0203	HYDROCHLORIC ACID

Isopto Carpine Excipient Strategy and Commercial Opportunities

Last updated: October 17, 2026

Isopto Carpine is an ophthalmic pilocarpine hydrochloride solution used primarily to reduce elevated intraocular pressure in glaucoma and ocular hypertension. Its commercial opportunity is driven less by novel active-ingredient protection and more by formulation differentiation: preservative-free multidose delivery, unit-dose packaging, improved tolerability, longer ocular residence, and new pilocarpine indications such as presbyopia.

The core product uses a conventional aqueous formulation with pilocarpine hydrochloride, boric acid, sodium citrate, sodium chloride, and purified water or water for injection. The established formulation creates a low technical barrier for generic entry, but patient adherence, ocular-surface tolerability, packaging, and indication-specific dosing create opportunities for differentiated products.[1]

What is Isopto Carpine and how is it formulated?

Isopto Carpine is the branded ophthalmic solution of pilocarpine hydrochloride. Commercial strengths include 1%, 2%, and 4% solutions. The product is administered topically to the eye and acts as a direct cholinergic agonist, producing miosis and ciliary muscle contraction.

Isopto Carpine formulation profile

Attribute	Isopto Carpine profile
Active ingredient	Pilocarpine hydrochloride
Dosage form	Sterile ophthalmic solution
Commercial strengths	1%, 2%, and 4%
Primary indications	Glaucoma and ocular hypertension
Route	Topical ophthalmic
pH strategy	Acidic aqueous solution, adjusted for stability and tolerability
Buffer system	Boric acid and sodium citrate
Tonicity agents	Sodium chloride
Vehicle	Purified water or water for injection
Packaging	Multidose ophthalmic bottle, subject to market-specific configuration
Key formulation risks	Hydrolysis, pH control, ocular irritation, microbial contamination, dosing frequency

The inactive ingredients are designed to control pH, osmolarity, and chemical stability rather than provide sustained release. The formulation is technically simple compared with emulsions, suspensions, gels, or lipid-based ophthalmic systems.[1]

What excipients are used in Isopto Carpine?

The principal excipients identified in product labeling are boric acid, sodium citrate, sodium chloride, and water. The label may also identify hydrochloric acid and sodium hydroxide as pH-adjustment agents.[1]

Boric acid

Boric acid contributes to buffering and tonicity control. It is widely used in ophthalmic products because it can support a physiologically acceptable osmolality profile while helping maintain formulation pH.

For a pilocarpine product, the buffer system must balance several factors:

• Chemical stability of pilocarpine hydrochloride
• Corneal and conjunctival tolerability
• Compatibility with the container-closure system
• Sterility and preservative performance
• Consistency across the 1%, 2%, and 4% strengths

Sodium citrate

Sodium citrate provides buffering capacity and helps stabilize the acidic aqueous formulation. Its concentration should be controlled because excessive buffer capacity can increase ocular discomfort and reduce the ability of tears to neutralize the administered dose.

Sodium chloride

Sodium chloride adjusts osmolality. A formulation that is substantially hypotonic or hypertonic may increase stinging, reflex tearing, and dose loss from the ocular surface. For a chronic glaucoma product, these tolerability factors can affect adherence.

Water and pH adjusters

Water is the vehicle. Hydrochloric acid and sodium hydroxide may be used to achieve the target pH. pH adjustment is a critical process parameter because pilocarpine stability, ocular comfort, and container compatibility are linked to the final pH.

How strong is the excipient and formulation protection for Isopto Carpine?

The original Isopto Carpine formulation has limited apparent product differentiation from a patent perspective. Pilocarpine ophthalmic solutions have been marketed for decades, and the basic excipient combination is conventional.

The principal barriers are regulatory and quality-related rather than composition-of-matter barriers:

Protection category	Likely strength for legacy Isopto Carpine
Pilocarpine composition-of-matter protection	Very low
Basic aqueous solution formulation	Low
Borate-citrate buffer system	Low
Strength-specific formulation protection	Low to moderate
Container-closure and manufacturing know-how	Moderate
Preservative-free multidose delivery	Moderate to high if supported by device IP
Sustained-release ocular delivery	High if clinically validated and patented
New method of use	Moderate to high, depending on claims and clinical data
Brand recognition and physician familiarity	Moderate

A competitor can generally approach the product through an abbreviated new drug application if it can demonstrate pharmaceutical equivalence, bioequivalence where applicable, quality, sterility, and acceptable labeling. The basic excipients are unlikely to prevent generic substitution.

When does Isopto Carpine lose exclusivity?

Isopto Carpine is an old small-molecule ophthalmic product. Its original regulatory and patent exclusivity periods have expired. Any current commercial protection is therefore more likely to arise from trademarks, manufacturing controls, device claims, later formulation patents, or market-specific regulatory exclusivity than from the original pilocarpine product.

The FDA Orange Book should be reviewed for current listed patents and exclusivity entries associated with the relevant NDA and strength. The age of the product means that a generic entrant would typically focus on an ANDA rather than a 505(b)(2) pathway, unless it seeks a materially different formulation, delivery system, or indication.[2]

Paragraph IV challenge risk

A Paragraph IV certification could arise if an ANDA applicant challenges a listed patent associated with the brand product. For a legacy pilocarpine solution, the practical risk is likely concentrated in:

• Later-issued formulation patents
• Device or container-closure patents
• Preservative-free multidose systems
• Method-of-use patents
• Patents covering new strengths or dosing regimens

The basic pilocarpine hydrochloride solution is unlikely to support meaningful new patent protection without a distinct technical feature.

What excipient strategies could improve Isopto Carpine?

1. Preservative-free unit-dose formulation

A preservative-free unit-dose product is the most straightforward commercial opportunity. Chronic glaucoma patients may experience ocular-surface disease, irritation, dryness, or intolerance to preserved ophthalmic products. Unit-dose packaging removes the need for a multidose preservative system but increases packaging cost and waste.

Commercial advantages include:

• Improved suitability for preservative-sensitive patients
• Potential use after ocular surgery
• Reduced exposure to benzalkonium chloride where present
• Premium pricing relative to standard generic solution
• Easier positioning for long-term therapy

The principal disadvantages are higher manufacturing cost, greater packaging volume, and less convenient storage.

2. Preservative-free multidose bottle

A preservative-free multidose product offers a stronger commercial proposition than unit-dose packaging if the device can maintain sterility after repeated use. The formulation itself may remain similar to Isopto Carpine, while the value resides in the bottle, valve, tip, microbial barrier, and use instructions.

This strategy can support device patents and create a higher regulatory hurdle than a conventional generic solution. The sponsor must establish sterility maintenance, dose uniformity, extractables and leachables, container compatibility, and in-use stability.

3. Reduced-buffer formulation

A lower-buffer or near-buffer-free formulation could reduce stinging and allow the tear film to normalize ocular pH more rapidly. The tradeoff is lower resistance to pH drift and potentially greater sensitivity to manufacturing variation.

This strategy requires careful assessment of:

• Pilocarpine degradation
• pH drift over shelf life
• Osmolality
• Visible and subvisible particles
• Ocular comfort
• Interaction with the primary container

4. Viscosity-enhanced formulation

Increasing viscosity can extend ocular residence time and reduce drainage through the nasolacrimal system. Candidate excipients could include low concentrations of hydroxypropyl methylcellulose, hydroxypropyl cellulose, povidone, or hyaluronic acid.

The risks include blurred vision, increased drop retention at the lid margin, altered dosing accuracy, preservative interactions, and more difficult sterile filtration. A viscosity-enhanced pilocarpine product may be better suited to a 505(b)(2) pathway than a standard ANDA if it produces a clinically meaningful difference.

5. In situ gel or mucoadhesive delivery

A pH-triggered, ion-sensitive, or thermosensitive gel could prolong exposure while reducing dosing frequency. This would create greater differentiation but also greater development risk.

Potential commercial benefits include:

• Once- or twice-daily dosing
• Improved adherence
• Reduced systemic drainage
• Lower peak ocular irritation
• Opportunity for new method-of-use claims

The development burden would include dose uniformity, rheology, ocular residence, comfort, visual effects, and comparative efficacy.

What formulations are protected by newer pilocarpine products?

Newer pilocarpine products show that the active ingredient can support differentiated commercial products when paired with new excipient, packaging, dosing, or indication strategies.

QLOSI

QLOSI, developed by Orasis Pharmaceuticals, is a pilocarpine hydrochloride ophthalmic solution approved in 2023 for the treatment of presbyopia in adults. Its commercial positioning differs from Isopto Carpine because it targets near-vision improvement rather than chronic intraocular-pressure reduction.[3]

The product demonstrates that a pilocarpine formulation can be commercially renewed through:

• A new indication
• A different concentration
• A defined dosing regimen
• Preservative-free packaging
• Clinical data supporting a refractive or functional benefit

Vuity

Vuity, developed by Allergan, is a pilocarpine hydrochloride ophthalmic solution approved for presbyopia. Its formulation and clinical positioning are distinct from Isopto Carpine’s glaucoma use.[4]

For investors and developers, QLOSI and Vuity establish a relevant precedent: pilocarpine is not limited to legacy glaucoma products. New delivery systems and indications can create separate regulatory and commercial assets even when the active ingredient is old.

How does Isopto Carpine compare with newer pilocarpine products?

Product	Active ingredient	Primary indication	Commercial differentiation
Isopto Carpine	Pilocarpine hydrochloride	Glaucoma and ocular hypertension	Legacy multidose solution; multiple strengths
Generic pilocarpine ophthalmic solutions	Pilocarpine hydrochloride	Glaucoma and ocular hypertension	Price and pharmacy substitution
Vuity	Pilocarpine hydrochloride	Presbyopia	New indication, dosing, and clinical positioning
QLOSI	Pilocarpine hydrochloride	Presbyopia	Preservative-free product and new indication
Future sustained-release products	Pilocarpine or combination active	Glaucoma or presbyopia	Reduced dosing frequency and improved exposure control

The key competitive distinction is not the molecule. It is the product system: concentration, dosing frequency, preservative profile, delivery device, indication, and evidence of patient benefit.

What manufacturing and IP barriers affect commercial entry?

A conventional generic Isopto Carpine product has manageable manufacturing requirements:

1. Source pharmaceutical-grade pilocarpine hydrochloride.
2. Prepare a controlled aqueous buffer solution.
3. Sterile-filter or aseptically manufacture the product.
4. Fill into a qualified ophthalmic container.
5. Demonstrate sterility, stability, assay, impurities, particulate limits, and dose uniformity.
6. Establish container-closure integrity and in-use performance.

The most important manufacturing risks are microbial contamination, pH drift, degradation, particulate formation, and compatibility with the bottle or dropper tip.

A differentiated product faces greater barriers. Preservative-free multidose systems require validated microbial protection without relying on a conventional chemical preservative. Viscosity-enhanced and gel products require more complex process controls. Sustained-release inserts, punctal plugs, contact lenses, and ocular implants introduce device-drug combination-product requirements.

Geographic coverage

Patent and regulatory rights must be evaluated separately by jurisdiction. A formulation patent may be enforceable in the United States but expired, absent, or narrower in Europe, Japan, Canada, or emerging markets. Commercial planning should also account for:

• Country-specific generic substitution rules
• Local preservative restrictions
• Multidose sterility standards
• Reimbursement for branded ophthalmic products
• Local manufacturing requirements
• Trademark status for Isopto Carpine and competing brands

Which commercial opportunities are most attractive?

Opportunity	Technical complexity	Regulatory pathway	Commercial potential
Low-cost generic 1%, 2%, or 4% solution	Low	ANDA	Moderate volume, low margin
Preservative-free unit-dose solution	Moderate	ANDA or 505(b)(2), depending on differences	Moderate to high niche value
Preservative-free multidose bottle	High	ANDA or 505(b)(2)	High if device performs reliably
Reduced-buffer comfort formulation	Moderate	ANDA or 505(b)(2)	Moderate
Viscosity-enhanced solution	Moderate to high	505(b)(2) likely	Moderate to high
Sustained-release pilocarpine	High	505(b)(2) or NDA	High if dosing frequency falls
Pilocarpine for presbyopia	High clinical and commercial risk	NDA or 505(b)(2)	High but competitive
Combination glaucoma product	High	505(b)(2) or NDA	High if adherence improves

The best near-term opportunity is a preservative-free product with a differentiated delivery device. The highest-value long-term opportunity is sustained-release or reduced-frequency pilocarpine delivery, but that path requires clinical evidence and stronger IP.

What patent litigation and settlement risks apply?

The legacy Isopto Carpine product is unlikely to generate substantial current litigation solely over the basic pilocarpine solution. Litigation risk increases if a sponsor introduces:

• A patented bottle or sterile-barrier system
• A new method of treating presbyopia
• A reduced-frequency dosing regimen
• A sustained-release formulation
• A combination with another glaucoma drug
• A clinically differentiated concentration

Settlement agreements involving generic entry would depend on any active listed patents, the applicant’s certification, and the sponsor’s willingness to permit an authorized or licensed generic. Current litigation and settlement status must be confirmed through FDA listings and federal court records for the relevant product and patent numbers.[2,5]

Key Takeaways

• Isopto Carpine is a legacy pilocarpine hydrochloride ophthalmic solution available in 1%, 2%, and 4% strengths.
• Its core excipient system uses boric acid, sodium citrate, sodium chloride, and water, with acid or base for pH adjustment.
• The basic formulation has limited standalone patent strength and faces generic substitution risk.
• Preservative-free unit-dose and multidose products offer the clearest formulation-led opportunities.
• Viscosity enhancement, mucoadhesion, and sustained-release delivery could support 505(b)(2) products and new patent claims.
• QLOSI and Vuity demonstrate that pilocarpine can support new commercial value through presbyopia indications and differentiated product design.
• Manufacturing controls, sterile packaging, device performance, and ocular tolerability are more important entry barriers than the legacy excipient composition.
• The strongest commercial opportunity is a differentiated product that reduces dosing burden or preservative exposure while preserving reliable ocular delivery.

FAQs

Is Isopto Carpine preservative-free?

The exact preservative status depends on the labeled presentation and market-specific product configuration. The applicable FDA labeling and package insert should control the assessment for a particular bottle or strength.[1]

Can a company launch a generic Isopto Carpine product?

Yes. A company can pursue an ANDA for a pharmaceutically equivalent pilocarpine hydrochloride ophthalmic solution, subject to FDA requirements for quality, sterility, stability, labeling, and applicable equivalence standards.[2]

Does pilocarpine have commercial value outside glaucoma?

Yes. Pilocarpine has been commercialized for presbyopia, including products such as Vuity and QLOSI. New indications can create commercial value despite the age of the active ingredient.[3,4]

What excipient is most important for improving pilocarpine eye-drop tolerability?

No single excipient determines tolerability. Buffer strength, pH, osmolality, preservative exposure, viscosity, and drop volume collectively affect stinging, reflex tearing, and ocular-surface comfort.

Is a sustained-release pilocarpine product patentable?

Potentially. Patentability would depend on the specific formulation, delivery device, release profile, treatment method, and claim scope. A generic aqueous solution would not provide the same level of technical differentiation.

References

1. U.S. Food and Drug Administration. (n.d.). Isopto Carpine: Pilocarpine hydrochloride ophthalmic solution prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2023). QLOSI (pilocarpine hydrochloride ophthalmic solution) prescribing information.

4. U.S. Food and Drug Administration. (2021). VUITY (pilocarpine hydrochloride ophthalmic solution) prescribing information.

5. U.S. Food and Drug Administration. (n.d.). Patent and exclusivity information. FDA.